Stocks Health care OBIO
NASDAQ · Health careOrchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings, Inc. brought in $32M of revenue over the twelve months to June 30, 2026, up 986.1% from a year earlier. It posted a net loss of $59M. In fiscal 2025 capital spending exceeded operating cash flow by $49.5M. At June 30, 2026 it held $20.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Orchestra BioMed Holdings, Inc. does
Orchestra BioMed Holdings, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker OBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $33.5M | -$52.7M | -$1.11 | -$49.5M |
| 2024 | $2.6M | -$61M | -$1.66 | -$50.8M |
| 2023 | $2.8M | -$49.1M | -$1.48 | -$46.2M |
| 2022 | $3.5M | -$33.6M | -$2.24 | -$29.9M |
| 2021 | n/a | -$378.8K | -$0.26 | n/a |
Where OBIO ranks in Health care
Dividends
It paid out $20M in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2022 | n/a | $20M | n/a |
Latest SEC filings
What Orchestra BioMed Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026
- June 23, 2026
- June 23, 2026
- June 16, 2026Additional proxy material DEFA14A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026
- April 29, 2026Activist stake changed SCHEDULE 13D/A
- April 29, 2026
- April 29, 2026Additional proxy material DEFA14A
- April 29, 2026Proxy statement DEF 14A
Insider trades
What the people running Orchestra BioMed Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $58.6K and sold $74.1K worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Hochman David PSee Remarks, Director | Shares withheld for tax | 3,283 | $19.1K |
| September 10, 2026 | Hochman David PSee Remarks, Director | Shares withheld for taxindirect | 3,283 | $19.1K |
| September 3, 2026 | Hochman David PSee Remarks, Director | Bought | 10,000 | $47.9K |
| September 1, 2026 | Sherman DarrenSee Remarks, Director | Soldpre-planned (10b5-1) | 15,000 | $74.1K |
| August 26, 2026 | Aiello JoshuaPrincipal Accounting Officer | Shares withheld for tax | 203 | $1.1K |
| August 26, 2026 | Sherman DarrenSee Remarks, Director | Shares withheld for tax | 4,925 | $25.9K |
| August 26, 2026 | Sherman DarrenSee Remarks, Director | Boughtindirect | 2,000 | $10.7K |
| August 26, 2026 | Taylor Andrew LawrenceChief Financial Officer | Shares withheld for tax | 3,076 | $16.2K |
Questions about OBIO
What does Orchestra BioMed Holdings, Inc. do?
Orchestra BioMed Holdings, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker OBIO.
Is Orchestra BioMed Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $59M on revenue of $32M.
How much revenue does Orchestra BioMed Holdings, Inc. make?
Over the twelve months to June 30, 2026 Orchestra BioMed Holdings, Inc. reported revenue of $32M. That is 986.1% more than a year earlier.
When did Orchestra BioMed Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 11, 2026.
Similar companies
Compare OBIO with
Follow OBIO
Get an email when Orchestra BioMed Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow OBIO: get an email when it filesWhere the numbers come from
Financial figures are the values Orchestra BioMed Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.